vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and PLEXUS CORP (PLXS). Click either name above to swap in a different company.
PLEXUS CORP is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.0× Elanco Animal Health Inc). PLEXUS CORP runs the higher net margin — 4.3% vs -24.1%, a 28.4% gap on every dollar of revenue. On growth, PLEXUS CORP posted the faster year-over-year revenue change (18.7% vs 12.2%). Over the past eight quarters, PLEXUS CORP's revenue compounded faster (7.2% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Plex Systems, Inc. is an American software company based in Troy, Michigan. The company develops and markets the Plex Manufacturing Cloud, a software as a service (SaaS) or cloud computing ERP for manufacturing.
ELAN vs PLXS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.2B |
| Net Profit | $-276.0M | $49.8M |
| Gross Margin | 51.5% | 10.2% |
| Operating Margin | -22.6% | 5.3% |
| Net Margin | -24.1% | 4.3% |
| Revenue YoY | 12.2% | 18.7% |
| Net Profit YoY | -3350.0% | 27.5% |
| EPS (diluted) | $-0.55 | $1.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | — | $41.2M | ||
| Q4 25 | $-276.0M | — | ||
| Q3 25 | $-34.0M | — | ||
| Q2 25 | $11.0M | — | ||
| Q1 25 | $67.0M | — | ||
| Q4 24 | $-8.0M | — | ||
| Q3 24 | $364.0M | — | ||
| Q2 24 | $-50.0M | — |
| Q1 26 | — | 9.9% | ||
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — |
| Q1 26 | — | 5.1% | ||
| Q4 25 | -22.6% | — | ||
| Q3 25 | -4.4% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | -5.0% | — | ||
| Q3 24 | 54.3% | — | ||
| Q2 24 | -2.7% | — |
| Q1 26 | — | 3.8% | ||
| Q4 25 | -24.1% | — | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | -0.8% | — | ||
| Q3 24 | 35.3% | — | ||
| Q2 24 | -4.2% | — |
| Q1 26 | — | $1.51 | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.13 | — | ||
| Q4 24 | $-0.01 | — | ||
| Q3 24 | $0.73 | — | ||
| Q2 24 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $303.1M |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $1.5B |
| Total Assets | $13.4B | $3.4B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $248.8M | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $505.0M | — | ||
| Q2 25 | $539.0M | — | ||
| Q1 25 | $487.0M | — | ||
| Q4 24 | $468.0M | — | ||
| Q3 24 | $490.0M | — | ||
| Q2 24 | $416.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $6.5B | — | ||
| Q3 25 | $6.7B | — | ||
| Q2 25 | $6.8B | — | ||
| Q1 25 | $6.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.5B | — | ||
| Q2 24 | $5.9B | — |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $13.4B | — | ||
| Q3 25 | $13.6B | — | ||
| Q2 25 | $13.7B | — | ||
| Q1 25 | $12.9B | — | ||
| Q4 24 | $12.6B | — | ||
| Q3 24 | $13.3B | — | ||
| Q2 24 | $13.8B | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | — |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.0M | — | ||
| Q3 25 | $219.0M | — | ||
| Q2 25 | $237.0M | — | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $177.0M | — | ||
| Q3 24 | $162.0M | — | ||
| Q2 24 | $200.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | — | ||
| Q3 25 | $127.0M | — | ||
| Q2 25 | $180.0M | — | ||
| Q1 25 | $-69.0M | — | ||
| Q4 24 | $130.0M | — | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $166.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | — | ||
| Q3 25 | 11.2% | — | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | -5.8% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 14.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 2.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
PLXS
| Asia-Pacific | $652.0M | 56% |
| Americas | $397.0M | 34% |
| Europe, Middle East and Africa | $116.0M | 10% |
